https://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySat, 27 Jul 2024 12:35:57 +0200Fri, 19 Jul 2024 16:53:00 +0200https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002893-pip01-20-m03Opinion/decision on a Paediatric investigation plan (PIP): Spikevax (previously COVID-19 Vaccine Moderna), elasomeran,imelsomeram,davesomeran, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases;Vaccines, PIP number: P/0152/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002893-pip01-20-m03Fri, 19 Jul 2024 16:53:00 +0200Human medicinehttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5791-en_3.pdfSpikevax : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5791-en_3.pdfThu, 04 Jul 2024 15:02:00 +0200Human medicinehttps://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-modernaHuman medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 46, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-modernaThu, 04 Jul 2024 10:38:00 +0200Human medicine